Pascal TEER Device Performs Well in Patients With Complex Anatomy
The registry patients, who had degenerative MR, were ineligible for randomization in CLASP IID due to their complexity.
Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The registry patients, who had degenerative MR, were ineligible for randomization in CLASP IID due to their complexity.
Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment
Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program
September 18, 2022—Medtronic announced the presentation of long-term results from the SYMPLICITY HTN-3 clinical trial. In the randomized control
Medtronic (NYSE:MDT) announced data from multiple trials supporting its transcatheter heart valve replacement devices.